Testing effectiveness (Phase 2)Study completedNCT02132130
What this trial is testing
Safety, Tolerability and Efficacy for CGF166 in Patients With Unilateral or Bilateral Severe-to-profound Hearing Loss
Who this might be right for
Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss
Novartis Pharmaceuticals 22